LB Pharmaceuticals, Inc. LBRX 深 滬
已收盤 02-06 16:00:00 美东时间
23.82
-0.040
-0.17%
華盛通- 最 高24.53
- 今 開24.03
- 成交量 26.38万股
- 最 低 23.165
- 昨 收 23.86
- 總市值 6.03亿
- 52周最高 24.9499
- 市盈率 靜 --
- 換手率 1.04%
- 52周最低 13.36
- 委 比 -88.57%
- 總股本 2529.91万
- 歷史最高 24.9499
- 量 比 1.32
- 振 幅 5.72%
- 歷史最低 13.36
- 每 手 1
- 風險率 2.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多LB Pharmaceuticals Announces Up To $100M Private Offering of 4.72M Shares at $21.17 Each to Fund Clinical Trials
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases,
02-05 21:12
LB Pharmaceuticals Initiates Phase 2 Trial Evaluating Efficacy And Safety Of LB-102 In Patients With Bipolar Depression; Topline Data Expected In 1Q 2028
Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophreniaNEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX),
01-26 21:03
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
LB Pharmaceuticals appoints Ellen Rose as Senior Vice President, Corporate Affairs, and Lindsay Beaupre as Senior Vice President, People and Culture. Both bring extensive experience to support the company’s development of LB-102, a novel benzamide for schizophrenia and bipolar depression. LB-102 is advancing into pivotal Phase 3 trials for schizophrenia and Phase 2 for bipolar depression, with potential for additional indications.
01-06 12:00
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Stifel Maintains Buy on LB Pharmaceuticals, Raises Price Target to $35
Stifel analyst Paul Matteis maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and raises the price target from $27 to $35.
2025-12-11 21:28
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals granted its new Chief Commercial Officer, Kaya Pai Panandiker, an equity award under the 2025 Equity Incentive Plan, including an option to purchase 195,000 shares at $21.36 per share, vesting over four years. The company’s lead product, LB-102, is a Phase 3-ready oral drug for schizophrenia and bipolar depression, with potential expansion into other neuropsychiatric conditions. LB Pharmaceuticals focuses on developing innovati...
2025-12-10 22:04
LB Pharmaceuticals Added To Russell 2000 And Russell 3000 Indexes Effective Dec. 22, 2025
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced the Company has been included in the Russell 2000® Index and the broad-market Russell 3000® Index,
2025-12-09 21:06
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference
LB Pharmaceuticals' CEO Heather Turner will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. The presentation will discuss LB-102, a Phase 3-ready oral medication for schizophrenia and bipolar depression, which showed significant benefits in a Phase 2 trial. The company aims to advance LB-102 into further clinical trials and explore additional indications.
2025-11-24 13:00
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points o...
2025-11-18 00:39
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals授予新任高级副总裁James Rawls一份股权奖，包括9万股期权，为期十年，行权价为$14.61，分四年解锁。公司重点介绍了其处于III期临床试验阶段的药物LB-102，用于治疗精神分裂症和双相抑郁症，具备广泛扩展潜力。
2025-11-12 21:15
